PLUS1
Best deals to access real time data! |
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Chimerix Inc | CMRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.06 | 2.94% | 2.10 | 2.13 | 2.035 | 2.08 | 2.04 | 10:03:06 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 2.10 | 2.11 | 0.01 | 0.47% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 280 | 105,232 | $ 2.07 | $ 217,791 | 518,139 | 1.25 - 4.40 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:03:06 | 30 | $ 2.10 | USD |
Chimerix Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 128.90M | 61.38M | $ -69.47M | -1.43 | - | 59.93M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Chimerix News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/10/2019 | 13:56 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 12/10/2019 | 07:30 | GlobeNewswire Inc. | Chimerix Presents Updated Results from Phase 2 Clinical.. |
| 11/13/2019 | 16:15 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/08/2019 | 12:29 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) |
| 11/07/2019 | 12:45 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/06/2019 | 17:01 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 11/05/2019 | 08:26 | Edgar (US Regulatory) | Quarterly Report (10-q) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CMRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.98 | 2.18 | 1.96 | 2.04 | 233,155 | 0.12 | 6.06% |
| 1 Month | 2.13 | 2.44 | 1.95 | 2.13 | 325,300 | -0.03 | -1.41% |
| 3 Months | 1.34 | 2.86 | 1.28 | 1.97 | 645,007 | 0.76 | 56.72% |
| 6 Months | 3.71 | 4.0999 | 1.25 | 2.02 | 602,786 | -1.61 | -43.4% |
| 1 Year | 2.71 | 4.40 | 1.25 | 2.33 | 523,116 | -0.61 | -22.51% |
| 3 Years | 4.88 | 6.6399 | 1.25 | 3.48 | 329,376 | -2.78 | -56.97% |
| 5 Years | 39.88 | 58.07 | 1.25 | 9.54 | 573,399 | -37.78 | -94.73% |
Chimerix Description
| Chimerix Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, oral antivirals in areas of unmet medical needs. The company's focus is on novel nucleosides with activity against influenza, norovirus, CMV, and BK virus, among others. It derives its revenue from two sources contracts and grants, and collaborations and licensing. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of DNA viruses, including smallpox, adenoviruses, and the human herpesviruses. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are currently available. |
